Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2014

Open Access 01-12-2014 | Research

Silencing BMP-2 expression inhibits A549 and H460 cell proliferation and migration

Authors: Heying Chu, Hailan Luo, Huaqi Wang, Xiaonan Chen, Ping Li, Yong Bai, Furui Zhang, Ruirui Cheng, Shanshan Chen, Yuanyuan Wang, Guoqiang Zhao, Guojun Zhang

Published in: Diagnostic Pathology | Issue 1/2014

Login to get access

Abstract

Background

Bone morphogenetic protein 2 (BMP-2) is a member of the TGF-β superfamily that is closely correlated with many malignancies, particularly lung cancer. However, the effects of silenced BMP-2 on lung cancer cell proliferation and migration are not clear.

Methods

Using quantitative real-time RT-PCR, BMP-2 mRNA expression was detected in 61 non-small cell lung cancer (NSCLC) samples. Survival curves were generated using follow-up data. Relationships between clinical or pathological characteristics and prognosis were analyzed. Cell viability assays and transwell migration assays were used to evaluate the effects of BMP-2 silencing on cell proliferation and migration of A549 and H460 cells.

Results

BMP-2 mRNA expression was higher in NSCLC tissues compared to matched adjacent normal tissues (P < 0.01). High BMP-2 expression levels were significantly associated with the occurrence of lymph node metastases and tumor stage (P < 0.05). There were significant differences in survival curves between groups with metastatic lymph nodes and non-metastatic lymph nodes, as well as between groups with low BMP-2 expression and groups with high BMP-2 expression. In addition, we observed decreased proliferation and migration rates of the NSCLC-derived cell lines A549 and H460 that were transfected with siBMP-2 (P < 0.05).

Conclusion

BMP-2 mRNA is overexpressed in NSCLC samples and is a risk factor for survival in patients with NSCLC. BMP-2 silencing can significantly inhibit A549 and H460 cell proliferation and migration.

Virtual slides

The virtual slide(s) for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​4263254471298866​
Literature
1.
2.
3.
4.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics. CA Cancer J Clin. 2009, 59 (4): 225-249.PubMedCrossRef
5.
Spira A, Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med. 2004, 350 (4): 379-392.PubMedCrossRef
6.
Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA: Novel regulators of bone formation: molecular clones and activities. Science. 1988, 242: 1528-1534.PubMedCrossRef
7.
Hogan BL: Bone morphogenetic proteins: Multifunctional regulators of vertebrate development. Genes Dev. 1996, 10: 1580-1594.PubMedCrossRef
8.
Fei ZH, Yao CY, Yang XL, Huang XE, Ma SL: Serum BMP-2 Up-regulation as an indicator of poor survival in advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev. 2013, 14 (9): 5293-5299.PubMedCrossRef
9.
Choi YJ, Kim ST, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH: The serum bone morphogenetic protein-2 level in non-small-cell lung cancer patients. Med Oncol. 2012, 29 (2): 582-588.PubMedCrossRef
10.
Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P, Langenfeld J: The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis. 2003, 9 (24): 1445-1454.CrossRef
11.
Langenfeld EM, Kong Y, Langenfeld J: Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. Oncogene. 2006, 25: 685-692.PubMedCrossRef
12.
Langenfeld EM, Langenfeld J: Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res. 2004, 2: 141-149.PubMed
13.
Katsuno Y, Hanyu A, Kanda H, Ishikawa Y, Akiyama F, Iwase T, Ogata E, Ehata S, Miyazono K, Imamura T: Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene. 2008, 27: 6322-6333.PubMedCrossRef
14.
Ye L, Lewis-Russell JM, Kyanaston HG, Jiang WG: Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol. 2007, 22: 1129-1147.PubMed
15.
Alarmo EL, Kallioniemi A: Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?. Endocr Relat Cancer. 2010, 17: R123-R139.PubMedCrossRef
16.
Thawani JP, Wang AC, Than KD, Lin CY, La Marca F, Park P: Bone morphogenetic proteins and cancer: review of the literature. Neurosurgery. 2010, 66: 233-246.PubMedCrossRef
17.
Willette RN, Gu JL, Lysko PG, Anderson KM, Minehart H, Yue T: BMP-2 gene expression and effects on human vascular smooth muscle cells. J Vasc Res. 1999, 36: 120-125.PubMedCrossRef
18.
Cunningham NS, Paralkar V, Reddi AH: Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression. Proc Natl Acad Sci. 1992, 89: 11740-11744.PubMedPubMedCentralCrossRef
19.
An J, Rosen V, Cox K, Beauchemin N, Sullivan AK: Recombinant human bone morphogenetic protein-2 induces a hematopoietic microenvironment in the rat that supports the growth of stem cells. Exp Hematol. 1996, 24: 768-775.PubMed
20.
Kim WJ, Mohan RR, Wilson SE: Effect of PDGF, IL-1alpha, and BMP2/4 on corneal fibroblast chemotaxis: expression of the platelet-derived growth factor system in the cornea. Invest Ophthalmol Vis Sci. 1999, 40: 1364-1372.PubMed
21.
Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K: Two major Smad pathways in TGF-b superfamily signaling. Genes Cells. 2002, 7: 1191-204.PubMedCrossRef
22.
Gao X, Cao Y, Yang W, Duan C, Aronson JF, Rastellini C, Chao C, Hellmich MR, Ko TC: BMP2 inhibits TGF-β-induced pancreatic stellate cell activation and extracellular matrix formation. Am J Physiol Gastrointest Liver Physiol. 2013, 304 (9): G804-G813.PubMedPubMedCentralCrossRef
23.
Kang MH, Kim JS, Seo JE, Oh SC, Yoo YA: BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Exp Cell Res. 2010, 316 (1): 24-37.PubMedCrossRef
24.
Helbing T, Herold EM, Hornstein A, Wintrich S, Heinke J, Grundmann S, Patterson C, Bode C, Moser M: Inhibition of BMP activity protects epithelial barrier function in lung injury. J Pathol. 2013, 231 (1): 105-116.PubMedCrossRef
25.
Langenfeld EM, Kong Y, Langenfeld J: Bone morphogenetic protein-2-induced transformation involves the activation of mammalian target of rapamycin. Mol Cancer Res. 2005, 3 (12): 679-684.PubMedCrossRef
26.
Langenfeld EM, Bojnowski J, Perone J, Langenfeld J, Langenfeld BS: Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg. 2005, 80: 1028-1032.PubMedCrossRef
27.
Bieniasz M, Oszajca K, Eusebio M, Kordiak J, Bartkowiak J, Szemraj J: The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients. Lung Cancer. 2009, 66 (3): 319-326.PubMedCrossRef
28.
Liu S, Li Y, Qi W, Zhao Y, Huang A, Sheng W, Lei B, Lin P, Zhu H, Li W, Shen H: Expression of Tiam1 predicts lymph node metastasis and poor survival of lung adenocarcinoma patients. Diagn Pathol. 2014, 9: 69-PubMedPubMedCentralCrossRef
29.
Zheng S, Du Y, Chu H, Chen X, Li P, Wang Y, Ma Y, Wang H, Zang W, Zhang G, Zhao G: Analysis of MAT3 gene expression in NSCLC. Diagn Pathol. 2013, 8: 166-PubMedPubMedCentralCrossRef
30.
Liu F, Zhou Y, Zhou D, Kan M, Niu X, Zhang Z, Zhang D, Tao L, He L, Zhan L, Liu Y: Whole DNA methylome profiling in lung cancer cells before and after epithelial-to-mesenchymal transition. Diagn Pathol. 2014, 9: 66-PubMedPubMedCentralCrossRef
31.
Hao J, Lee R, Chang A, Fan J, Labib C, Parsa C, Orlando R, Andresen B, Huang Y: DMH1, a small molecule inhibitor of BMP type I receptors, suppresses growth and invasion of lung cancer. PLoS One. 2014, 3 (9): e90748-1–6CrossRef
32.
Ye XY, Niu XM, Tang NW, Xu YH, Li ZM, Yu YF, Lu S, Chen SW: Adenovirus mediated knockdown of bone morphogenetic protein 2 inhibits human lung cancer growth and invasion in vitro and in vivo. Int J Immunopathol Pharmacol. 2012, 25 (4): 967-976.PubMed
Metadata
Title
Silencing BMP-2 expression inhibits A549 and H460 cell proliferation and migration
Authors
Heying Chu
Hailan Luo
Huaqi Wang
Xiaonan Chen
Ping Li
Yong Bai
Furui Zhang
Ruirui Cheng
Shanshan Chen
Yuanyuan Wang
Guoqiang Zhao
Guojun Zhang
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2014
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-9-123

Other articles of this Issue 1/2014

Diagnostic Pathology 1/2014 Go to the issue

Methodology

Association between cyclin D1 G870A polymorphism and cervical cancer risk: a cumulative meta-analysis involving 2,864 patients and 3,898 controls

Research

p16INK4a expression in retinoblastoma: a marker of differentiation grade

Letter to the Editor

Low neonatal blood glucose levels in cesarean-delivered term newborns at Khartoum Hospital, Sudan

Research

Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations

Case Report

Coexistent hairy cell leukaemia and hepatosplenic t-cell lymphoma: a case report

Research

Bioinformatics analysis of Rab GDP dissociation inhibitor beta and its expression in non-small cell lung cancer